{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:04:45Z","timestamp":1789538685750,"version":"build-2803163510"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hyperprogressive disease (HPD) refers to a phenomenon characterized by a significant acceleration in tumor growth during treatment with immune-checkpoint inhibitors (ICIs), far exceeding the pre-treatment growth rate, leading to rapid deterioration in the patient\u2019s condition. HPD typically occurs within the first two months of treatment and often results in early mortality. While sex differences in immune responses have been extensively studied, the relationship between sex and HPD risk remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched MEDLINE (PubMed), Embase, and Scopus databases to identify studies reporting HPD in patients treated with ICIs, with available gender-stratified data. The search encompassed all records from database inception until 30 June 2025. Meta-analyses were performed using RevMan 5.4.1 software, with pooled odds ratios and 95% confidence intervals calculated under either fixed-effects or random-effects model, depending on heterogeneity. The primary objective was to evaluate the association between biological sex and the risk of HPD. The research protocol has been registered on the PROSPERO platform (CRD420261324007).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      This meta-analysis included 20 studies involving 2,291 patients (1,612 male patients and 679 female patients), all of which were retrospective. The overall incidence of HPD was 18.67% in male patients and 18.26% in female patients. Pooled analysis revealed no statistically significant association between biological sex and the risk of HPD development (\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u00a0=\u00a027%;\n                      <jats:italic>p<\/jats:italic>\n                      =\u00a00.13).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings demonstrate that sex should not be considered a determinative factor for HPD risk in patients receiving ICIs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1860831","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T05:31:39Z","timestamp":1789536699000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Sex and risk of hyperprogressive disease in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Jia","family":"Zhu","sequence":"first","affiliation":[{"name":"Department of Geriatric Oncology, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Peking University Cancer Hospital Yunnan","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changling","family":"Tu","sequence":"additional","affiliation":[{"name":"Department of Geriatric Oncology, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Peking University Cancer Hospital Yunnan","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70412","article-title":"The role of immune checkpoint inhibitors in cancer therapy: mechanism and therapeutic advances","volume":"6","author":"Chen","year":"2025","journal-title":"Medcomm"},{"key":"B2","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12943-016-0525-3","article-title":"Essential role of miRNAs in orchestrating the biology of the tumor microenvironment","volume":"15","author":"Frediani","year":"2016","journal-title":"Mol Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in efficacy and toxicity of systemic treatments: an undervalued issue in the era of precision oncology","volume":"36","author":"\u00d6zdemir","year":"2018","journal-title":"J Clin Oncol Oficial J Am Soc Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.Epi-11-0246","article-title":"Sex disparities in cancer mortality and survival","volume":"20","author":"Cook","year":"2011","journal-title":"Cancer Epidemiology Biomarkers Prevention: A Publ Am Assoc For Cancer Research Cosponsored by Am Soc Prev Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2023.11.014","article-title":"Associations between sex-specific reproductive factors and risk of new-onset lung cancer among female patients","volume":"166","author":"Zhang","year":"2024","journal-title":"Chest"},{"key":"B7","doi-asserted-by":"publisher","first-page":"eaba3066","DOI":"10.1126\/science.aba3066","article-title":"The impact of sex on gene expression across human tissues","volume":"369","author":"Oliva","year":"2020","journal-title":"Sci (New York NY)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00515","article-title":"Hyperprogression after immune-checkpoint inhibitor treatment: characteristics and hypotheses","volume":"10","author":"Zang","year":"2020","journal-title":"Front Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.111934","article-title":"Regulatory T cells as crucial trigger and potential target for hyperprogressive disease subsequent to PD-1\/PD-L1 blockade for cancer treatment","volume":"132","author":"Ren","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12929-024-01004-x","article-title":"Targeting MDM2 in Malignancies is a promising strategy for overcoming resistance to anticancer immunotherapy","volume":"31","author":"Sun","year":"2024","journal-title":"J BioMed Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-16-1741","article-title":"Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1\/PD-L1","volume":"23","author":"Champiat","year":"2017","journal-title":"Clin Cancer Research: Off J Am Assoc For Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1186\/s12885-022-09941-2","article-title":"Inhibition of hyperprogressive cancer disease induced by immune-checkpoint blockade upon co-treatment with meta-tyrosine and p38 pathway inhibitor","volume":"22","author":"Montagna","year":"2022","journal-title":"BMC Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31999","article-title":"Hyperprogressive disease in early\u2010phase immunotherapy trials: clinical predictors and association with immune\u2010related toxicities","volume":"125","author":"Kanjanapan","year":"2019","journal-title":"Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx178","article-title":"Hyperprogression during anti-PD-1\/PD-L1 therapy in patients with recurrent and\/or metastatic head and neck squamous cell carcinoma","volume":"28","author":"Sa\u00e2da-Bouzid","year":"2017","journal-title":"Ann Oncol Off J Eur Soc For Med Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13505","article-title":"Sarcopenia and high NLR are associated with the development of hyperprogressive disease after second-line pembrolizumab in patients with non-small-cell lung cancer","volume":"202","author":"Petrova","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-022-01349-y","article-title":"Pattern of disease progression during third-line or later chemotherapy with nivolumab associated with poor prognosis in advanced gastric cancer: a multicenter retrospective study in Japan","volume":"26","author":"Aoki","year":"2022","journal-title":"Gastric Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14539","article-title":"Clinical outcomes of hyperprogression based on volumetry in non\u2010small cell lung cancer after immune checkpoint inhibitor treatment","volume":"13","author":"Kim","year":"2022","journal-title":"Thorac Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e000488","DOI":"10.1136\/esmoopen-2019-000488","article-title":"Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer","volume":"4","author":"Aoki","year":"2019","journal-title":"ESMO Open"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.237768","article-title":"Hyperprogressive disease in patients with non\u2013small cell lung cancer treated with checkpoint inhibitors: the role of 18F-FDG PET\/CT","volume":"61","author":"Castello","year":"2020","journal-title":"J Nucl Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2252692","DOI":"10.1080\/21645515.2023.2252692","article-title":"Hyperprogressive disease during PD-1 blockade in patients with advanced pancreatic cancer","volume":"19","author":"Chen","year":"2023","journal-title":"Hum Vaccines Immunotherapeutics"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-0975-7","article-title":"Multicentre biomarker cohort study on the efficacy of nivolumab treatment for gastric cancer","volume":"123","author":"Hagi","year":"2020","journal-title":"Br J Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"100989","DOI":"10.1016\/j.tranon.2020.100989","article-title":"Anti-PD1 checkpoint inhibitor with or without chemotherapy for patients with recurrent and metastatic nasopharyngeal carcinoma","volume":"14","author":"Jin","year":"2021","journal-title":"Transl Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"15330338231209129","DOI":"10.1177\/15330338231209129","article-title":"Hyperprogressive disease (HPD) in solid tumours receiving immune checkpoint inhibitors in a real-world setting","volume":"22","author":"Kanjanapan","year":"2023","journal-title":"Technol Cancer Res Treat"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz123","article-title":"Hyperprogressive disease during PD-1\/PD-L1 blockade in patients with non-small-cell lung cancer","volume":"30","author":"Kim","year":"2019","journal-title":"Ann Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-020-03293-9","article-title":"Clinical outcomes of nivolumab in patients with advanced non-small cell lung cancer in real-world practice, with an emphasis on hyper-progressive disease","volume":"146","author":"Kim","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.05.033","article-title":"Comprehensive clinical and genetic characterization of hyperprogression based on volumetry in advanced non\u2013small cell lung cancer treated with immune checkpoint inhibitor","volume":"14","author":"Kim","year":"2019","journal-title":"J Thorac Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e197621","DOI":"10.1001\/jamanetworkopen.2019.7621","article-title":"Serological markers associated with response to immune checkpoint blockade in metastatic gastrointestinal tract cancer","volume":"2","author":"Lu","year":"2019","journal-title":"JAMA Netw Open"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2024.2312628","article-title":"Noninvasive radiomic biomarkers for predicting pseudoprogression and hyperprogression in patients with non-small cell lung cancer treated with immune checkpoint inhibition","volume":"13","author":"Li","year":"2024","journal-title":"Oncoimmunology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e211136","DOI":"10.1001\/jamanetworkopen.2021.1136","article-title":"Definition, incidence, and challenges for assessment of hyperprogressive disease during cancer treatment with immune checkpoint inhibitors","volume":"4","author":"Park","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B30","doi-asserted-by":"crossref","DOI":"10.1007\/s10120-018-00922-8","article-title":"Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer","volume":"22","author":"Sasaki","year":"2019","journal-title":"Gastric Cancer"},{"key":"B31","article-title":"Hyperprogressive disease rarely occurs during checkpoint inhibitor treatment for advanced melanoma","volume":"70","author":"Schuiveling","year":"2020","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"B32","doi-asserted-by":"publisher","first-page":"5171","DOI":"10.3390\/jcm11175171","article-title":"Blood based biomarkers as predictive factors for hyperprogressive disease","volume":"11","author":"Yildirim","year":"2022","journal-title":"J Clin Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"100673","DOI":"10.1016\/j.eclinm.2020.100673","article-title":"Predicting hyperprogressive disease in patients with advanced hepatocellular carcinoma treated with anti-programmed cell death 1 therapy","volume":"31","author":"Zhang","year":"2020","journal-title":"EClinicalMedicine"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2019.09.009","article-title":"Hyperprogressive disease in patients with urothelial carcinoma or renal cell carcinoma treated with PD-1\/PD-L1 inhibitors","volume":"18","author":"Hwang","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"9999","DOI":"10.1073\/pnas.1822001116","article-title":"PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer","volume":"116","author":"Kamada","year":"2019","journal-title":"PNAS"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.843707","article-title":"Hyperprogressive disease in patients suffering from solid Malignancies treated by immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"12","author":"Zhao","year":"2022","journal-title":"Front Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13594","article-title":"Prediction model for hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitors","volume":"11","author":"Choi","year":"2020","journal-title":"Thorac Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09071-2","article-title":"Concurrent loss of the Y chromosome in cancer and T cells impacts outcome","volume":"642","author":"Chen","year":"2025","journal-title":"Nature"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06234-x","article-title":"Y chromosome loss in cancer drives growth by evasion of adaptive immunity","volume":"619","author":"Abdel-Hafiz","year":"2023","journal-title":"Nature"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2022.2124449","article-title":"Sex difference in response to non-small cell lung cancer immunotherapy: an updated meta-analysis","volume":"54","author":"Liang","year":"2022","journal-title":"Ann Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"105069","DOI":"10.1016\/j.critrevonc.2025.105069","article-title":"Sex differences in immunotherapy plus chemotherapy: A systematic review and meta-analysis","volume":"218","author":"Abdu","year":"2026","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1860831\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T05:31:40Z","timestamp":1789536700000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1860831\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":41,"alternative-id":["10.3389\/fimmu.2026.1860831"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1860831","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"article-number":"1860831"}}